BiotechTube

Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% Lotion

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head Lice

Conditions

Head Lice

Trial Timeline

Oct 2, 2017 → Dec 18, 2017

NCT ID
NCT03337490

About Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% Lotion

Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% Lotion is a phase 3 stage product being developed by Mayne Pharma Group for Head Lice. The current trial status is completed. This product is registered under clinical trial identifier NCT03337490. Target conditions include Head Lice.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03337490Phase 3Completed

Competing Products

20 competing products in Head Lice

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
Cemiplimab + CetuximabEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Placebo + LY2300559Eli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
44
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
52
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
cevimeline hydrochlorideDaiichi SankyoPhase 3
77
Docetaxel + Erlotinib + ChemotherapyAstellas PharmaPhase 2
52
ErlotinibAstellas PharmaPhase 1
33
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
41
Ivermectin Lotion, 0.5% + SKLICE (ivermectin) Lotion, 0.5% + Vehicle of the Test productSun PharmaceuticalPhase 1
33
Drug Combination TherapySun PharmaceuticalPhase 2
52
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
Lenvatinib + Pembrolizumab + PlaceboEisaiPhase 3
77
Lenvatinib + Pembrolizumab + PlaceboEisaiPhase 3
77

Other Products from Mayne Pharma Group

Sporanox + LozanocApproved
77
Halobetasol Topical FoamApproved
77
Doxycycline Hyclate Delayed-Release 200 mgApproved
77
Slow release oral morphine (SROM) + MethadonePhase 3
69
Permethrin Cream, 5% + ElimitePhase 3
69